BioXcel Therapeutics (BTAI) Inventory Average (2022 - 2026)

BioXcel Therapeutics' Inventory Average history runs 5 years deep, the most recent figure standing at $611000.0 for Q1 2026.

• On a quarterly basis, Inventory Average fell 7.49% year-over-year to $611000.0 in Q1 2026; TTM through Mar 2026 was $611000.0, a 7.49% decrease from a year earlier, with the FY2025 full-year figure at $700500.0, down 47.53% from the prior year.
• Inventory Average rose to $611000.0 in Q1 2026 per BTAI's latest filing, from $590500.0 in the prior quarter.
• Across five years, Inventory Average topped out at $2.6 million in Q2 2024 and bottomed at $482500.0 in Q3 2025.
• The 5-year median for Inventory Average is $1.5 million (2022), against an average of $1.4 million.
• Across the five-year window, Inventory Average jumped 86.66% in 2023 and slumped 77.57% in 2025, its largest moves.
• Year by year, Inventory Average stood at $1.7 million in 2022, then gained by 18.16% to $2.0 million in 2023, then plunged by 45.02% to $1.1 million in 2024, then sank by 46.42% to $590500.0 in 2025, then rose by 3.47% to $611000.0 in 2026.
• Per Business Quant, the three latest BTAI Inventory Average figures stand at $611000.0 (Q1 2026), $590500.0 (Q4 2025), and $482500.0 (Q3 2025).